Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Journal of Biopharmaceutical Statistics|November 11, 2017
Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Advanced multiplicity problemsGautier Paux, Alex DmitrienkoJournal of Biopharmaceutical Statistics|November 28, 2017
Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Traditional multiplicity problemsGautier Paux, Alex DmitrienkoJournal of Biopharmaceutical Statistics|September 23, 2015
Tradeoff-based optimization criteria in clinical trials with multiple objectives and adaptive designsAlex Dmitrienko, Gautier Paux, Erik Pulkstenis, et al.Biometrical Journal. Biometrische Zeitschrift|November 10, 2011
Development of gatekeeping strategies in confirmatory clinical trialsAlex Dmitrienko, Brian A Millen, Thomas Brechenmacher, et al.Statistics in Medicine|March 2, 2016
Implementation of adaptive methods in early-phase clinical trialsGina R Petroni, Nolan A Wages, Gautier Paux, et al.Pharmaceutical Statistics|March 3, 2023
Utilization of treatment effect on a surrogate endpoint for planning a study to evaluate treatment effect on a final endpointHui Quan, Zhixing Xu, Junxiang Luo, et al.Pharmaceutical Statistics|January 8, 2020
Applications of Bayesian analysis to proof-of-concept trial planning and decision makingHui Quan, Xun Chen, Yu Lan, et al.Therapeutic Innovation & Regulatory Science|June 22, 2024
Use of Seamless Study Designs in Oncology Clinical Development- A Survey Conducted by IDSWG Oncology Sub-teamYingwen Dong, Gautier Paux, Kristine Broglio, et al.Breast Cancer Research : BCR|November 11, 2023
AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancerMario Campone, François-Clément Bidard, Patrick Neven, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2024
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5Javier Cortés, Sara A Hurvitz, Joyce O'Shaughnessy, et al.Pageof 2